Current stage-Stage IV - Page 2 of 9 Posts on Medivizor
Navigation Menu

Current stage-Stage IV Posts on Medivizor

Does adding chemotherapy to cytoreductive surgery improve the outcome of patients with peritoneal metastases from colorectal cancer?

Does adding chemotherapy to cytoreductive surgery improve the outcome of patients with peritoneal metastases from colorectal cancer?

Posted by on Apr 11, 2021 in Colorectal cancer | 0 comments

In a nutshell This study evaluated the benefit of adding hyperthermic intraperitoneal chemotherapy (HIPEC) to cytoreductive surgery (CS) for the treatment of colorectal cancer (CRC) that has spread to the peritoneum (the lining of the abdomen that covers all abdominal organs). The study found that HIPEC added to CS did not improve the outcomes of...

Read More

Do single or combined immune checkpoint inhibitors improve outcomes in patients with advanced non-small cell lung cancer?

Do single or combined immune checkpoint inhibitors improve outcomes in patients with advanced non-small cell lung cancer?

Posted by on Apr 8, 2021 in Lung cancer | 0 comments

In a nutshell This article looked at the effectiveness and safety of first-line immune checkpoint inhibitors (ICIs) alone or as a combination compared to platinum-based chemotherapy (PBC) for advanced non-small cell lung cancer (NSCLC). The authors found that ICI therapy may improve the survival of these patients while having reduced side...

Read More

Searching for patients to trial an experimental medication for advanced solid tumors.

Searching for patients to trial an experimental medication for advanced solid tumors.

Posted by on Jan 28, 2021 in Lung cancer | 0 comments

In a nutshell This trial is aiming to examine the safety and effectiveness of experimental treatment DF6002 alone or in combination with nivolumab (Opdivo) in the treatment of advanced solid tumors, including lung cancer. The main outcomes to be measured are drug toxicity and the response rate of patients to the drug. This trial is being carried out in...

Read More

Does continuous nivolumab improve outcomes in advanced non-small cell lung cancer?

Does continuous nivolumab improve outcomes in advanced non-small cell lung cancer?

Posted by on Jan 10, 2021 in Lung cancer | 0 comments

In a nutshell This study compared 1-year fixed-duration versus continuous nivolumab (Opdivo) for the treatment of previously treated advanced non-small-cell lung cancer (NSCLC). The authors found that continuing nivolumab beyond a fixed duration of 1-year may improve patient outcomes.  Some background NSCLC is the most common form of lung cancer....

Read More

Liver partition and portal vein ligation improves long-term outcomes of patients with colorectal cancer and liver metastases

Liver partition and portal vein ligation improves long-term outcomes of patients with colorectal cancer and liver metastases

Posted by on Dec 31, 2020 in Colorectal cancer | 0 comments

In a nutshell This study investigated the long-term outcomes of patients with colorectal cancer (CRC) and liver metastases (LM; cancer spread to the liver) undergoing the ALPPS (associating liver partition and portal vein ligation) procedure. Researchers suggested that patients with LM that were unfit for surgical removal achieved positive long-term...

Read More

Searching for patients with advanced breast cancer to trial an experimental combination treatment.

Searching for patients with advanced breast cancer to trial an experimental combination treatment.

Posted by on Dec 13, 2020 in Breast cancer | 0 comments

In a nutshell This trial is looking to examine the safety and effectiveness of a new drug called CYH33 in combination with olaparib (Lynparza) for the treatment of advanced solid tumors including breast cancer. The main outcomes that are to be measured are side effects and the response rate to the treatment. This trial is being carried out in...

Read More

Treating postmenopausal women with HER2- and hormone-receptor positive metastatic breast cancer with lapatinib, trastuzumab and aromatase inhibitor

Treating postmenopausal women with HER2- and hormone-receptor positive metastatic breast cancer with lapatinib, trastuzumab and aromatase inhibitor

Posted by on Oct 23, 2020 in Breast cancer | 0 comments

In a nutshell The study evaluated outcomes of lapatinib (Tykerb), trastuzumab (Herceptin), and aromatase inhibitor (AI) in postmenopausal women with human epidermal growth factor receptor 2-positive (HER2+) and hormone receptor-positive (HR+) metastatic breast cancer (MBC). The authors found that the combination was safe and effective in such...

Read More

Searching for patients with advanced triple-negative breast cancer to trial a treatment combination

Searching for patients with advanced triple-negative breast cancer to trial a treatment combination

Posted by on Sep 6, 2020 in Breast cancer | 0 comments

In a nutshell This trial is aiming to examine the effectiveness of ipatasertib in combination with atezolizumab (Tecentriq) and paclitaxel (Taxol) for the treatment of advanced triple-negative breast cancer (TNBC) that cannot be surgically removed. The main outcomes to be measured in this trial is survival without progression of the disease and...

Read More

The effectiveness and safety of regorafenib in older patients with advanced pretreated colorectal cancer

The effectiveness and safety of regorafenib in older patients with advanced pretreated colorectal cancer

Posted by on May 24, 2020 in Colorectal cancer | 0 comments

In a nutshell This study investigated the effectiveness and safety of regorafenib (Stivarga) treatment in older patients with colorectal cancer (CRC). Researchers suggested that this treatment has similar effects in younger and older patients. Some background CRC is the third most common cancer worldwide. More than half are diagnosed in patients older...

Read More

Regular physical activity is associated with improved outcomes for advanced colorectal cancer

Posted by on Oct 20, 2019 in Colorectal cancer | 0 comments

In a nutshell This study investigated the effectiveness of physical activity (PA) on the outcomes of patients with advanced colorectal cancer. Researchers suggested that regular PA is associated with better outcomes for these patients. Some background Colorectal cancer is the third most common cancer worldwide. A significant number of patients...

Read More